Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019593006> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2019593006 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAIntratumoral heterogeneity is evident as distinct subpopulations of cancer cells within and between tumor lesions that profoundly impact therapeutic response and patient outcome. While the advent of targeted therapies to exploit a tumor's dependence on critical proliferative or survival pathways has significantly improved patient outcomes in a range of solid tumor types, it is also apparent that targeted therapeutics do not help all molecularly selected patients and even when clinical benefit is observed, it is often of limited duration. To address this question, we have explored the invariably fatal adult brain tumor glioblastoma multiforme (GBM). Heterogeneous forms of the epidermal growth factor receptor (EGFR) arise through amplification or mutation as signature pathogenetic events in this highly aggressive disease. While EGFR deregulation promotes tumor cell proliferation, drug resistance and tumor survival, functional blockade of the EGFR kinase activity alone does not achieve maximal therapeutic benefit. Since intratumoral heterogeneity represents a major impediment to the development of effective therapeutics in GBM, we sought to identify small molecules cytotoxic to glioma cells engineered to overexpress either wildtype (WT), constitutively active mutant EGFR-vIII, kinase-dead (KD) form or a basal level of EGFR-WT using a live cell-based, high-throughput screen (HTS) of ∼2,000 FDA-approved or bioactive compounds. Our screen revealed that the Hsp90 inhibitor ganetespib (STA-9090, Synta Pharmaceuticals, Lexington, MA) was highly cytotoxic (IC50 ∼20nM) to glioma cells that overexpressed each of the EGFR forms. Real-time measurements were then performed to demonstrate that ganetespib at nM concentrations reduced the proliferation of brain tumor cells expressing EGFR-WT, -vIII or KD forms, induced apoptosis and inhibited glioma migration. Ganetespib also potently reduced the proliferation of human GBM patient-derived tumor-initiating stem cells but not that of untransformed glial cells. Ganetespib effectively impaired the growth of subcutaneously implanted human brain tumor xenotransplants that expressed either EGFR-WT, -vIII or both EGFR forms placed in immunocompromised mice. In addition, ganetespib provided a survival benefit compared to untreated mice. The Hsp90 inhibitor ganetespib is a highly potent agent that impairs the growth-promoting functional kinase-dependent and independent activities of EGFR to overcome context-dependent intratumoral heterogeneity with potential benefits for GBM patients.Citation Format: James J. Driscoll, Nitin S. Narayanan, Sajjeev Jagannathan. The Hsp90 inhibitor ganetespib overcomes EGFR-based intratumoral heterogeneity to block glioma proliferation. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-140. doi:10.1158/1538-7445.AM2014-LB-140" @default.
- W2019593006 created "2016-06-24" @default.
- W2019593006 creator A5005848743 @default.
- W2019593006 creator A5035898667 @default.
- W2019593006 creator A5082992040 @default.
- W2019593006 date "2014-09-30" @default.
- W2019593006 modified "2023-09-26" @default.
- W2019593006 title "Abstract LB-140: The Hsp90 inhibitor ganetespib overcomes EGFR-based intratumoral heterogeneity to block glioma proliferation" @default.
- W2019593006 doi "https://doi.org/10.1158/1538-7445.am2014-lb-140" @default.
- W2019593006 hasPublicationYear "2014" @default.
- W2019593006 type Work @default.
- W2019593006 sameAs 2019593006 @default.
- W2019593006 citedByCount "1" @default.
- W2019593006 countsByYear W20195930062019 @default.
- W2019593006 crossrefType "proceedings-article" @default.
- W2019593006 hasAuthorship W2019593006A5005848743 @default.
- W2019593006 hasAuthorship W2019593006A5035898667 @default.
- W2019593006 hasAuthorship W2019593006A5082992040 @default.
- W2019593006 hasConcept C104317684 @default.
- W2019593006 hasConcept C121608353 @default.
- W2019593006 hasConcept C126322002 @default.
- W2019593006 hasConcept C154317977 @default.
- W2019593006 hasConcept C184235292 @default.
- W2019593006 hasConcept C202751555 @default.
- W2019593006 hasConcept C205260736 @default.
- W2019593006 hasConcept C2775932338 @default.
- W2019593006 hasConcept C2777560012 @default.
- W2019593006 hasConcept C2778227246 @default.
- W2019593006 hasConcept C2779438470 @default.
- W2019593006 hasConcept C502942594 @default.
- W2019593006 hasConcept C55493867 @default.
- W2019593006 hasConcept C71924100 @default.
- W2019593006 hasConcept C86803240 @default.
- W2019593006 hasConcept C95444343 @default.
- W2019593006 hasConceptScore W2019593006C104317684 @default.
- W2019593006 hasConceptScore W2019593006C121608353 @default.
- W2019593006 hasConceptScore W2019593006C126322002 @default.
- W2019593006 hasConceptScore W2019593006C154317977 @default.
- W2019593006 hasConceptScore W2019593006C184235292 @default.
- W2019593006 hasConceptScore W2019593006C202751555 @default.
- W2019593006 hasConceptScore W2019593006C205260736 @default.
- W2019593006 hasConceptScore W2019593006C2775932338 @default.
- W2019593006 hasConceptScore W2019593006C2777560012 @default.
- W2019593006 hasConceptScore W2019593006C2778227246 @default.
- W2019593006 hasConceptScore W2019593006C2779438470 @default.
- W2019593006 hasConceptScore W2019593006C502942594 @default.
- W2019593006 hasConceptScore W2019593006C55493867 @default.
- W2019593006 hasConceptScore W2019593006C71924100 @default.
- W2019593006 hasConceptScore W2019593006C86803240 @default.
- W2019593006 hasConceptScore W2019593006C95444343 @default.
- W2019593006 hasLocation W20195930061 @default.
- W2019593006 hasOpenAccess W2019593006 @default.
- W2019593006 hasPrimaryLocation W20195930061 @default.
- W2019593006 hasRelatedWork W1593299612 @default.
- W2019593006 hasRelatedWork W1864746645 @default.
- W2019593006 hasRelatedWork W2002144745 @default.
- W2019593006 hasRelatedWork W2142216607 @default.
- W2019593006 hasRelatedWork W2296687919 @default.
- W2019593006 hasRelatedWork W2469307120 @default.
- W2019593006 hasRelatedWork W2499073646 @default.
- W2019593006 hasRelatedWork W2564580923 @default.
- W2019593006 hasRelatedWork W2566881126 @default.
- W2019593006 hasRelatedWork W2728483795 @default.
- W2019593006 hasRelatedWork W2739698651 @default.
- W2019593006 hasRelatedWork W2793329414 @default.
- W2019593006 hasRelatedWork W2803728085 @default.
- W2019593006 hasRelatedWork W2810278856 @default.
- W2019593006 hasRelatedWork W2887647057 @default.
- W2019593006 hasRelatedWork W2946994377 @default.
- W2019593006 hasRelatedWork W2953640541 @default.
- W2019593006 hasRelatedWork W3023849184 @default.
- W2019593006 hasRelatedWork W3118341957 @default.
- W2019593006 hasRelatedWork W562420810 @default.
- W2019593006 isParatext "false" @default.
- W2019593006 isRetracted "false" @default.
- W2019593006 magId "2019593006" @default.
- W2019593006 workType "article" @default.